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In pancreatic ductal adenocarcinoma (PDAC), the fi-
broblast growth factor receptor 1 (FGFR-1) IIIb iso-
form correlates with the inhibition of cancer cell pro-
liferation, migration, and invasion, whereas FGFR-1
IIIc enhances cancer cell proliferation. The FGFR-2
IIIb isoform is expressed in PDAC, and its expression
correlates with increased venous invasion. We exam-
ined the role of FGFR-2 IIIc in PDAC. FGFR-2 IIIc was
expressed in all six pancreatic cancer cell lines exam-
ined and was highest in PANC-1 cells. FGFR-2 IIIc was
abundant in the cancer cells from 83 of 117 PDAC
cases, which correlated with decreased duration to de-
velopment of liver metastasis after surgery. FGFR-2 IIIc-
transfected cells exhibited increased proliferation in
vitro and formed larger subcutaneous and orthotopic
tumors, the latter producing more liver metastases.
Moreover, FGF-2 exerted amore rapid stimulatory effect
on the levels of phosphorylated extracellular signal-
regulated kinase (p-ERK) in FGFR-2 IIIc stably trans-
fected PANC-1 cells, compared with control cells.
FGFR-2 IIIc-transfected cells also formed more spheres
and contained more side population cells. Suppression
of FGFR-2 IIIc expression inhibited the proliferation of
PANC-1 cells, whereas an anti-FGFR-2 IIIc antibody in-
hibited the proliferation and migration of PANC-1 cells.
Thus, high FGFR-2 IIIc levels in PDAC contribute to dis-
ease aggressiveness and confer to pancreatic cancer
cells features suggestive of cancer stem cells, indicating
that FGFR-2 IIIc may be a novel and important thera-
1928peutic target in PDAC. (Am J Pathol 2012, 180:1928–1941;
DOI: 10.1016/j.ajpath.2012.01.020)
Pancreatic ductal adenocarcinoma (PDAC) is one of the
most aggressive human malignancies, and long-term
survivors are few. Although the management and treat-
ment of patients with PDAC have improved in the last few
decades, the overall 5-year survival rate remains at5%,
and PDAC is the fourth leading cause of cancer death in
Japan and the United States.1 This poor prognosis is due
to the fact that PDAC is often locally invasive and is
associated with metastases at presentation, which
means that the cancer is not resectable. Moreover, those
patients who undergo resection frequently exhibit a high
incidence of local recurrence, lymph node and hepatic
metastasis, and peritoneal dissemination. At the molec-
ular level, the cancer cells in PDAC often harbor muta-
tions in the KRAS oncogene and the SMAD4, TP53, and
CDKN2A (alias p16Ink4A) tumor suppressor genes.2,3 A
high percentage of PDACs also overexpress a number of
growth factors and their receptors, including the epider-
mal growth factor receptor (EGFR), transforming growth
factor- (TGF-), Cripto-1 growth factor (CRGF), all three
TGF- isoforms, fibroblast growth factor 1 (FGF-1),
FGF-2, FGF-5, FGF-7 (also known as keratinocyte growth
factor, KGF), and KGFR/FGFR-2 IIIb.4,5 The concomitant
expression of KGF and its receptor in PDAC has been
correlated with increased VEGF-A expression, venous
invasion, and poor prognosis.5 These multiple alterations
in oncogenes and tumor suppressor genes in conjunc-
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growth factors and their receptors that activate aberrant
autocrine and paracrine pathways combine to contribute
to the biological aggressiveness of PDAC.
The FGF family consists of FGF-1, FGF-2, FGF-3
(proto-oncogene Int-2), FGF-4 (HST/K-FGF), FGF-5,
FGF-6, FGF-7, FGF-8 [androgen-induced growth factor
(AIGF)], glia activating factor (GAF) (FGF-9), FGF-10,
FGF-11 [FGF homologous factor 3 (FHF-3)], FGF-12
(FHF-1), FGF-13 (FHF-2), FGF-14 (FHF-4), and FGF-16 to
FGF-23.5,6 The FGFs bind to four distinct high-affinity
FGF receptors (FGFR-1 to FGFR-4) and to low-affinity
heparan sulfate proteoglycans that enhance ligand pre-
sentation to the high-affinity receptors.7 FGFRs are single
transmembrane receptors containing extracellular, trans-
membrane, and intracellular domains. The extracellular
domain of FGFRs is usually composed of three Ig-like
domains (I to III), and the alternative splicing of C-termi-
nal half of the third Ig-like domain generates IIIb and IIIc
isoforms in FGFR-1, FGFR-2, and FGFR-3. Expression of
the FGFR-1 IIIb isoform in pancreatic cancer cells inhibits
the proliferation, migration, and invasion of these cells,
whereas expression of the FGFR-1 IIIc isoform promotes
mitogenic signaling via the FRS2-MAPK pathways.8–11
In normal human tissues, FGFR-2 IIIb is mainly local-
ized in epithelial cells, whereas FGFR-2 IIIc is mostly
expressed in mesenchymal cells.12 Appropriate tissue-
specific expression of FGFR-2 IIIb or FGFR-2 IIIc, in con-
junction with the presence of appropriate ligands, is cru-
cial for maintenance of cellular homeostasis and function.
FGFs 1, 3, 7, 10, and 22 are reported to bind to FGFR-2
IIIb with high affinity, whereas FGFs 1, 2, 4, 6, 9, 17, and
18 bind to FGFR-2 IIIc with high affinity.13,14 Previously,
FGFs 1, 2, 5, and 7 were reported to be overexpressed in
PDAC.15–17 A significant positive correlation has been
demonstrated between FGF-7 and/or FGFR-2 IIIb ex-
pression and venous invasion, increased VEGF-A ex-
pression, and poor prognosis in PDAC patients.5
FGFR-2 IIIc expression has been reported in prostate
cancer, ovarian cancer, oral squamous cell carcinoma,
breast cancer, bladder cancer, and non-small-cell lung
cancer cells.18–23 Moreover, in rat prostate tumors loss of
FGFR-2 IIIb expression and gain of FGFR-2 IIIc expres-
sion was associated with tumor progression from andro-
gen dependence to androgen independence,24 whereas
in rat bladder cancer cells FGFR-2 IIIc expression has
been correlated with epithelial-to-mesenchymal transi-
tion, a process associated with tumor progression and
invasion.25 The relevance of FGFR-2 IIIc to human can-
cers is underscored by the presence of FGFR-2 IIIc in
breast cancer cells in women with more advanced stages
of the disease.26
Certain growth factors, including epidermal growth
factor (EGF) and FGF-2, promote formation of spheres
that contain cells with the potential for self-renewal, a
well-known feature of cancer stem cells (CSCs). These
cells promote cancer aggressiveness by enhancing pro-
liferation, invasion, metastasis, and chemoresistance.
Thus, CSCs are currently viewed as potentially important
therapeutic targets in several malignancies. Given the
observation that FGFR-2 IIIc is associated with aggres-sive cancer growth, we deemed it important to assess the
role of FGFR-2 IIIc in PDAC and to determine whether it
may contribute to a CSC niche. Accordingly, we exam-
ined the expression and biological actions of FGFR-2 IIIc
in pancreatic cancer cell lines and human cancer tissues.
We now report that FGFR-2 IIIc is expressed in pancre-
atic cancer cell lines and in PDAC tissues, and that
FGFR-2 IIIc promotes the proliferation and migration of
PDAC cells, and confers onto these cells CSC-like fea-
tures.
Materials and Methods
Materials
Materials were purchased as follows: Immobilon P trans-
fer membrane from Millipore (Yonezawa, Japan); FuGene
HD transfection reagent from Roche Diagnostics (Mann-
heim, Germany); FastPure RNA kit from Takara Bio (To-
kyo, Japan); high-capacity cDNA reverse transcription
kit, TaqMan gene expression assays for FGFR-3 IIIb
(Hs01005396_s1), FGFR-3 IIIc (Hs00997397_s1), FGFR4
(Hs01106908_s1), and 18S rRNA (Hs99999901_s1), Si-
lencer Select custom-designed siRNA (s275290 and
s275291), and Silencer negative control siRNA from Ap-
plied Biosystems (ABI; Life Technologies, Foster City,
CA); TransIT-siQUEST transfection reagent from Mirus
Bio (Madison, WI); M-PER mammalian protein extraction
reagent and SuperSignal West Dura chemiluminescent
substrates from Thermo Fisher Scientific (Rockford, IL);
G418 (Geneticin; Gibco BRL, Grand Island, NY);
Histofine simple stain MAX PO (R) kits, Histofine simple
stain MAX PO (M) kits, and peroxidase-conjugated
streptavidin from Nichirei (Tokyo, Japan); biotinylated an-
ti-guinea pig IgG from Vector Laboratories (Burlingame,
CA); HRP-conjugated goat anti-rabbit IgG secondary an-
tibodies from American Qualex (San Clemente, CA); hu-
man serum from Lonza (Walkersville, MD); Zenon rabbit
IgG labeling kit (Z-25351), Hoechst 33342 dye, and
Click-iT EdU Pacific Blue flow cytometry assay kit from
Invitrogen (Life Technologies, Carlsbad, CA); rabbit IgG
(ab37415) from Abcam (Cambridge, UK); 35-m filter,
8-m pore size cell culture insert, and BioCoat Matrigel
invasion chamber from BD Bioscience (Franklin Lakes,
NJ); guinea pig polyclonal anti-swine insulin antibody,
rabbit polyclonal anti-human IgG antibody, and mouse
monoclonal anti-Ki-67 antibody from Dako (Santa Bar-
bara, CA); rabbit polyclonal anti-extracellular signal-reg-
ulated kinase (ERK) 1 antibody (K-23) from Santa Cruz
Biotechnology (Santa Cruz, CA); mouse monoclonal anti-
human CD31 antibody from AbD Serotec (Kidlington,
UK); phospho-p44/42 MAPK (p-ERK) rabbit monoclonal
antibody from Cell Signaling Technology (Danvers, MA);
recombinant human basic fibroblast growth factor (bFGF,
FGF-2) from ReproCELL (Kanagawa, Japan); recombi-
nant human EGF from Austral Biologicals (San Ramon,
CA); ultra-low attachment surface plate from Corning
(Lowell, MA); recombinant human FGF-7 from R&D Sys-
tems (Minneapolis, MN); WST-8 cell counting kit from
Wako Pure Chemical Industries (Osaka, Japan); New Sil-
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Chemical (Tokyo, Japan). All other chemicals and reagents
were purchased from Sigma-Aldrich (St. Louis, MO).
Pancreatic Cancer Cell Lines
KLM-1, PANC-1, MIAPaCa-2, PK-1, and PK-8 PDAC cell
lines were obtained from the Cell Resource Center for
Biomedical Research, Institute of Development, Aging
and Cancer, Tohoku University (Sendai, Japan); the
Capan-1 pancreatic adenocarcinoma cell line was pur-
chased from American Type Culture Collection. The cells
were grown in the RPMI 1640 medium containing 10%
fetal bovine serum (FBS) at 37°C under a humidified 5%
CO2 atmosphere. Capan-1 cells were incubated under
the same conditions in RPMI 1640 medium with 15% FBS.
Patients and Tissues
Tissues from 117 patients with invasive PDAC were ob-
tained for this study. These patients received treatment at
Nippon Medical School Hospital (Tokyo, Japan) from
1995 to 2011. None of the patients received preoperative
chemotherapy and radiotherapy. The patients were 66
men and 51 women; the median age was 66.9 years
(range, 35 to 87 years). Clinicopathologic stage was de-
termined according to the TNM classification system of
the International Union Against Cancer (UICC) and was
additionally characterized under the Japan Pancreas So-
ciety classification (Table 1). Fifty-nine patients were
monitored after surgery; the median follow-up period was
15.6 months; 28 patients did not receive any postopera-
tive chemotherapy and 31 patients received adjuvant
chemotherapy after surgery. Of those receiving chemo-
therapy, 13 patients received tegafur-uracil and 12 pa-
tients received gemcitabine; 6 patients received tegafur-
uracil and gemcitabine. Paraffin-embedded specimens
were prepared for immunohistochemical analysis, as de-
scribed previously.27 This study was conducted in accor-
dance with the principles embodied in the Declaration of
Helsinki, 2008, and informed consent for the use of pan-
creatic tissues was obtained from each patient. Normal
pancreatic tissues were obtained from Human Digestive
Tissue Sets and Human Tissue Microarray 1 (both ob-
tained from Novagen, Darmstadt, Germany).
Quantitative Real-Time PCR of FGFR-2 IIIc in
Pancreatic Cancer Cells
All pancreatic cancer cells were grown in RPMI 1640
medium supplemented with 10% or 15% FBS for 48
hours. Total RNA extraction was performed using a Fast-
Pure RNA kit. Next, cDNA synthesis was performed using
a high-capacity cDNA reverse transcription kit according
to the manufacturer’s protocol. Quantitative real-time
PCR (q-PCR) was performed using an ABI StepOnePlus
system (Life Technologies). The real-time PCR primers
used for FGFR-2 IIIc were nt1693-1716 (5=-GGATATC-
CTTTCACTCTGCATGGT-3=) and nt1770-1794 (5=-TG-
GAGTAAATGGCTATCTCCAGGTA-3=) of human FGFR-2IIIc cDNA (102 bp; accession no. NM_000141.4). As
TaqMan probes, 5=-CAGTTCTGCCAGCGCCTG-
GAAGA-3= was used for FGFR-2 IIIc. PCR primers used
for FGFR-1 IIIb were nt1991-2010 (5=-ACCAGTCT-
GCGTGGCTCACT-3=) and nt2036-2052 (5=-TGCCGGC-
CTCTCTTCCA-3=) of human FGFR-1 IIIb cDNA (62 bp;
accession no. FJ809917.1). As TaqMan probes, 5=-CAC-
CAGACCTGTGGCAA-3= was used for FGFR-1 IIIb. PCR
primers used for FGFR-1 IIIc were nt1295-1316 (5=-
GGACTCTCCCATCACTCTGCAT-3=) and nt1381-1403
(5=-CCCCTGTGCAATAGATGATGATC-3=) of the human
FGFR-1 IIIc cDNA (109 bp; accession no. M34186.1). As
TaqMan probes, 5=-ACCGTTCTGGAAGCC-3= was used
for FGFR-1 IIIc. The PCR reaction mixture containing 2 L
of template cDNA, 10 L of TaqMan fast universal PCR
master mix and 1 L of each of TaqMan gene expression
assay was placed in a 96-well reaction plate. 18S rRNA,
as the internal positive control, was amplified using a
TaqMan gene expression assay. The optimized program
involved denaturation at 95°C for 20 seconds, followed
by 50 cycles of amplification (at 95°C for 1 second and at
60°C for 20 seconds) for FGFR-2 IIIc and 18S rRNA.
Results were expressed as target/18S rRNA, as an inter-
nal standard concentration ratio. Gene expression mea-
Table 1. Clinicopathologic Features and FGFR2 IIIc Expression
in Pancreatic Cancers
FGFR2 IIIc
P
value
Positive
(30%)
Negative
(30%)
Sample size n  84 n  33
Sex
F 40 11 NS
M 44 22
Age, years (mean  SD 
66.94  0.99)
66 40 15 NS
67 44 18
UICC classification
T (primary tumor)
T1 3 2 NS
T2 2 1
T3 37 5
T4 42 25
N (regional lymph nodes)
N0 32 10 NS
N1 52 23
M (distant metastasis)
M0 83 33 NS
M1 1 0
G (histological grading)
G1 37 10 NS
G2 36 14
G3 8 8
G4 3 1
UICC stage NS
I 7 4
II 73 26
III 4 3
None of the correlations were significant (P  0.05).
F, female; M, male; NS, not significant; UICC, International Union
Against Cancer.surements were performed in triplicate.
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To confirm the expression of FGFR-2 IIIc at the protein
level in pancreatic cancer, specific antibody against hu-
man FGFR-2 IIIc was prepared, as described previ-
ously.28 The anti-FGFR-2 IIIc antibody used was an affin-
ity-purified rabbit polyclonal antibody raised against a
peptide corresponding to amino acids AAGVNTTD-
KEIEVLYIR of the human FGFR-2 IIIc protein (accession
no. NM_000141.4). This sequence is located at the car-
boxyl-terminal half of the Ig loop closest to the transmem-
brane region and is specific for FGFR-2 IIIc.
Western Blot Analysis of FGFR-2 IIIc in
Pancreatic Cancer Cells
Protein extraction was performed according to the proto-
col involving the use of M-PER mammalian protein ex-
traction reagent. Briefly, cultured pancreatic cancer cells
were solubilized in M-PER reagent with protease inhibitor
cocktail for mammalian tissues. Lysates were centrifuged
for 10 minutes at 10,000  g to pellet cell debris. The
supernatants were collected and protein concentration
was measured by the Bradford method. The cleared pro-
tein lysates were subjected to SDS-PAGE under reducing
conditions, and the separated proteins were transferred
to Immobilon P transfer membranes, which were then
incubated for 16 hours at 4°C with the anti-FGFR-2 IIIc
antibody. The membranes were washed and incubated
with HRP-conjugated anti-rabbit IgG antibody for 60 min-
utes. After the wash, the blot was visualized by enhanced
chemiluminescence. The membrane was reblotted with
mouse monoclonal anti--actin antibody to confirm equal
loading.
Immunohistochemistry
The same anti-FGFR-2 IIIc antibody used for Western
blotting was also used for immunohistochemistry. Paraf-
fin-embedded sections (3 m thick) were subjected to
immunostaining using a Histofine simple stain MAX PO
(R) kit for FGFR-2 IIIc or a Histofine simple stain MAX PO
(M) kit for Ki-67 and CD31. After deparaffinization, en-
dogenous peroxidase activity was blocked by incubation
for 30 minutes with 0.3% hydrogen peroxide in methanol
for FGFR-2 IIIc and Ki-67 antibodies. The tissue sections
were then incubated with the anti-FGFR-2 IIIc antibody
(1:200 dilution), anti-Ki-67 antibody (1:100 dilution), or
CD31 (1:50 in dilution) in phosphate-buffered saline
(PBS) containing 1% bovine serum albumin (BSA) for 16
hours at 4°C. Bound antibodies were detected with the
Histofine simple stain MAX PO (R) or (M) reagent, using
diaminobenzidine tetrahydrochloride as the substrate.
For insulin staining, guinea pig polyclonal anti-porcine
insulin antibodies (1:1000 dilution), cross-reactive with
human insulin, and a biotinylated goat anti-guinea pig
IgG secondary antibody were used after incubation with
10% normal goat serum. Sections were then treated with
streptavidin-peroxidase complex, using diaminobenzi-dine tetrahydrochloride as the substrate. The sections
were then counterstained with Mayer’s hematoxylin. Neg-
ative control tissue sections were prepared by omitting
the primary antibody.
In Situ Hybridization
In situ hybridization was performed as previously re-
ported.5,29 Tissue sections were deparaffinized and in-
cubated at room temperature for 20 minutes with 0.2
mol/L HCl and then at 37°C for 15 minutes with 100
g/mL proteinase K. The sections were then postfixed for
5 minutes in PBS containing 4% paraformaldehyde, and
incubated twice for 15 minutes each with PBS containing
2 mg/mL glycine at room temperature and once in 50%
(v/v) formamide/2 standard saline citrate for 1 hour at
42°C before initiation of the hybridization reaction. The
hybridization buffer contained 0.6 mol/L NaCl, 1 mmol/L
EDTA, 10 mmol/L Tris-HCl (pH 7.6), 0.25% SDS, 200
mg/mL yeast tRNA, l Denhardt’s solution, 10% dextran
sulfate, 40% formamide, and 500 ng/mL of the indicated
digoxigenin-labeled riboprobe. Hybridization was per-
formed in a moist chamber for 16 hours at 42°C. The
sections were then washed sequentially with 2 stan-
dard saline citrate for 20 minutes at 42°C and 0.2 stan-
dard saline citrate for 20 minutes at 42°C. For immuno-
logical detection, a DIG nucleic acid detection kit (Roche
Diagnostics) was used. The sections were washed briefly
with buffer 1 (100 mmol/L Tris-HCl and 150 mmol/L NaCl,
pH 7.5), incubated with 1% (w/v) blocking reagents in
buffer 1 solution for 60 minutes at room temperature, and
with alkaline-phosphatase-conjugated polyclonal sheep
anti-digoxigenin Fab fragment containing 0.2% Tween 20
at l:2000 dilution for 60 minutes at room temperature. The
sections were then washed twice for 15 minutes at room
temperature with buffer 1 solution containing 0.2% Tween
20, equilibrated with buffer 3 solution (100 mmol/L Tris-
HCl, 100 mmol/L NaCl, 50 mmol/L MgCl2, pH 9.5) for 2
minutes, and incubated with a staining solution contain-
ing nitro blue tetrazolium and X-phosphate in a dark box
for 1 hour. After the reaction was stopped with TE buffer
(10 mmol/L Tris-HCl and 1 mmol/L EDTA, pH 8.0), the
sections were mounted in an aqueous mounting medium.
Construction of FGFR-2 IIIc Expression Vector
and Generation of Stably Transfected Clones
The full-length FGFR-2 IIIc cDNA fragment was ligated to
the 3= end of the human cytomegalovirus early promoter/
enhancer in pIRES2-EGFP eukaryotic expression vector.
Proper orientation of the insert was verified by DNA se-
quencing. Approximately 1  105 cells/2 mL of KLM-1
cells were transfected with 3 g of DNA using FuGene
HD transfection reagent, and the cells were passaged
and cultured with 600 g/mL of G418. Independent col-
onies were isolated by ring cloning, transferred to micro-
titer wells, and expanded in 300 g/mL of G418.
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Anti-FGFR-2 IIIc antibody was labeled with allophycocya-
nin using a Zenon rabbit IgG labeling kit according to the
manufacturer’s protocol. Cells were incubated for 20 min-
utes at 4°C in PBS containing 10% human serum. Cells
were then centrifuged briefly to remove the serum-con-
taining medium and incubated (5  105 cells/25 L) with
1 g of allophycocyanin-labeled anti-FGFR-2 IIIc anti-
body for 60 minutes in the dark at 4°C; 1 g of propidium
iodide was added, to label dead cells. Cells were washed
with cold PBS containing 2% FBS, and the cell suspen-
sion was passed through a 35-m filter. FGFR-2 IIIc ex-
pression was analyzed using a FACSAria II flow cytome-
ter (BD Bioscience, Franklin Lakes, NJ). Isotype-matched
rabbit IgG was used as a negative control.
Morphological Analysis of FGFR-2
IIIc-Transfected KLM-1 Cells
KLM-1 cells were cultured in 75-cm2 flasks in RPMI 1640
medium containing 10% FBS for 48 hours. The cells were
photographed using a Nikon Eclipse TE-2000-U system
at 200 magnification.
Cell Proliferation Assay
To monitor cell proliferation, nonradioactive cell prolifer-
ation assays were performed. Cells were plated at a
density of 5  103 cells per well in 96-well plates and
grown overnight in the RPMI 1640 medium supplemented
with 10% FBS. After 72 hours, cells were incubated with
WST-8 cell counting reagent for 4 hours at 37°C and the
optical density of the culture solution in the plate was
measured using an enzyme-linked immunosorbent assay
(ELISA) plate reader (Bio-Rad Laboratories, Hercules,
CA) at 450 nm. Analysis was performed in triplicate.
Heterotopic and Orthotopic Implantation of
FGFR-2 IIIc-Transfected KLM-1 Cells
To assess the effect of FGFR-2 IIIc expression on in vivo
tumorigenicity, 1  106 cells/animal were injected sub-
cutaneously into 6-week-old male athymic (nude) mice
(BALB/cA Jcl-nu/nu; CLEA Japan, Tokyo, Japan) (n  6
per cell line). Tumor volume was calculated as a  b2 
0.5, where a is the longest diameter and b is the shortest
diameter.30 The tumors were removed and cut in half.
Half of the tumor was fixed in 20% neutral-buffered for-
malin; the other half, used for orthotopic implantation,
was cut into 2-mm2 pieces. Under brief general inhalation
anesthesia with isoflurane and using 7.0 Prolene sutures,
KLM-1 fragments (2 mm2) were sutured onto the surface
of the tail of the pancreas of 6-week-old male NOD/Shi-
scid, IL-2null (NOG; Central Institute for Experimental
Animals, Kanagawa, Japan) and nude mice (n  4 per
cell line).31 The animals were monitored for 5 weeks.Sphere Formation Assay
An important feature of stem cells and CSCs (or cancer
initiating cells) is formation of cell spheres in floating
culture.32 Therefore, to determine whether pancreatic
cancer cells have CSC-like characteristics, we performed
sphere formation assays. KLM-1 cells (1000/well) were
plated in ultra-low attachment surface 24-well plates with
serum-free medium supplemented with or without FGF-2
(10 ng/mL) and EGF (20 ng/mL). After 7 days, the number
of spheres in each well was counted under a phase-
contrast microscope (Nikon Eclipse TE2000-U). Analysis
was performed in triplicate.
Flow Cytometry for Side Population Assay
Cells (1  106/mL) were incubated at 37°C for 10 min-
utes, and then 5 g/mL of Hoechst 33342 dye was
added. Verapamil (30 g/mL) was also added as a con-
trol. Cells were incubated at 37°C for 90 minutes, and
then washed twice with cold PBS containing 2% FBS.
Cells were suspended with PBS containing 1 mmol/L
EDTA, 25 mmol/L HEPES pH 7.0, and 1% FBS. Propidium
iodide (1 g) was added to label dead cells. The cell
suspension was passed through a 35-m filter. The ratio
of side population (SP) to major population (MP) was
analyzed using a BD FACSAria II flow cytometer. Analysis
was performed in triplicate.
Tumorigenicity of SP and MP Cells in
KLM-1 Cells
To examine the tumor formation ratio of SP and MP cells
in KLM-1 cells, we sorted each cells by flow cytometry, as
described above. A total number of 105, 104, 103, or 102
cells of SP and MP fractions were subcutaneously in-
jected into 6-week-old male NOD.CB17-Prkdcscid/J
(NOD/SCID) mice (Charles River Laboratories Japan, Ka-
nagawa, Japan). Tumor formation was determined after 5
weeks.
Cell Cycle Flow Cytometry
Cell cycle analysis was performed using a Click-iT EdU
Pacific Blue flow cytometry assay kit according to the
manufacturer’s protocol. In brief, 10 mol/L of 5-ethynyl-
2=-deoxyuridine (EdU) was added into culture medium,
and cells were incubated for 60 minutes at 37°C. Cells
were fixed with 4% paraformaldehyde for 60 minutes, and
then the EdU was labeled with Pacific Blue. 7-Aminoacti-
nomycin D (7-AAD) was added for measuring DNA con-
tent and cell cycle distribution, and cell cycle analysis
was performed using a BD FACSAria II flow cytometer.
Cell Signaling Pathway of FGFR-2
IIIc-Transfected Pancreatic Cancer
Cells were seeded in 60 mm-dish (2.5  105 cells) and
grown in RPMI 1640 medium supplemented with 10%
FBS for 24 hours. The cells were then washed with serum-
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hours, and recombinant FGF-2 (100 ng/mL) and/or hep-
arin (1 g/mL) was added to the plates. Protein was then
extracted and used for the Western blot analyses using
rabbit monoclonal anti-p-ERK (1:1000) and rabbit poly-
clonal anti-ERK antibodies (1:1000), as described above.
Single-Cell Movement Assay
Cells (5  103 per well) were seeded onto a four-well
glass-bottom dish and grown for 24 hours, and the me-
dium was then changed to RPMI 1640 supplemented
with 10% FBS, 100 ng/mL FGF-2, or 100 ng/mL FGF-7.
Cell movement in the presence of an anti-FGFR-2 IIIc
antibody or control IgG was then monitored for 24 hours
using a digital Nikon Eclipse TE 2000-E motorized in-
verted microscope, acquiring images every 5 minutes.
The total distance that individual cells traveled during 24
hours was determined using MetaMorph software version
7.6 (Universal Imaging, Marlow, UK).
Transfection of FGFR-2 IIIc siRNA
Down-regulation of FGFR-2 IIIc expression in PANC-1
cells was induced using siRNA. Two different types of
custom-designed siRNA against specific IIIc region of
FGFR-2 IIIc were purchased, and the sense sequence
was 5=-GGAAUGUAACUUUUGAGGATT-3= (s275290)
and 5=-GUGCUUGGCGGGUAAUCCUTT-3= (s275291)
(underlining denotes common sequences). The cells
were plated at a density of 1  105 cells in a 35-mm dish
and transfected with 5 nmol/L siRNAs for FGFR-2 IIIc and
Silencer negative control siRNA for control using TransIT-siQUEST according to the manufacturer’s protocol. To
confirm the effective transfection of siRNA in PANC-1
cells, total RNA was prepared at 24 hours after the trans-
fection and FGFR-2 IIIc mRNA levels were determined by
q-PCR.
Effects of Anti-FGFR-2 IIIc Antibody on Cell
Migration and Invasion
Cell migration was assessed using modified Boyden
chambers with uncoated inserts (6.4 mm in diameter;
8-m pores). Serum-free RPMI 1640 medium (500 L)
was placed in each upper chamber and RPMI 1640 me-
dium with 10% FBS (750 L) was into placed in each
lower chamber. PANC-1 cells were then plated on the
inner surface of the inserts at a density of 1  105 cells
per insert in the presence of either the anti-FGFR-2 IIIc
antibody or control IgG (100 g/mL), followed by incu-
bation at 37°C in a humidified 5% CO2 atmosphere. After
6 hours, the cells that moved to the outer surface of the
inserts were fixed, stained with a Diff-Quik staining kit
(Fisher Scientific, Pittsburgh, PA), and counted in five
high-power fields (20 objective). All assays were per-
formed in triplicate. Cell invasion assays were performed
using modified Boyden chambers in which the inner sur-
faces of the inserts were coated with Matrigel. Cell count-
ing was performed as described above.
Statistical Analysis
Results for cell proliferation or tumor volume are pre-
sented as means  SE. Data were compared between
different groups using Student’s t-test. Whenever indi-
Figure 1. Quantitative real-time PCR, Western
blotting, and flow cytometry analysis of FGFR-2
IIIc in pancreatic cancer cell lines. Cells of six
pancreatic cancer cell lines were grown in RPMI
1640 medium with 10% or 15% FBS for 48 hours.
A: FGFR-2 IIIc mRNA and other FGFRs were
expressed at variable levels in all six cell lines.
FGFR-2 IIIc mRNA levels were highest in
PANC-1 cells, which expressed 106-fold higher
levels of this mRNA moiety, compared with
Capan-1 cells. B: A band corresponding to 100-
kDa FGFR-2 IIIc protein was detected in all pan-
creatic cancer cell lines at levels that closely
paralleled the corresponding mRNA levels.
-Actin protein levels indicated nearly equal
loading of total proteins in all lanes. C: FGFR-2
IIIc-overexpressing cells were detected most fre-
quently in the PANC-1 and MIA PaCa-2 cell lines.
Isotype-matched rabbit IgG was used as a neg-
ative control (dotted line).
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analyze the correlation between FGFR-2 IIIc expression
and clinicopathologic features. Cumulative survival rates
were calculated by the Kaplan-Meier method, and the
significance of differences in survival rate was analyzed
by the log-rank test. Data were compared between mul-
tiple groups using one-way analysis of variance and then
Figure 2. Immunohistochemical analysis of FGFR-2 IIIc in normal pancre-
atic tissues. Serial tissue sections of normal pancreas stained for FGFR-2 IIIc
(A and C), insulin (B), and CD31 (D). FGFR-2 IIIc immunoreactivity was
weakly detected in the islet cells (asterisks), but not in ductal cells (ar-
rows), acinar cells, or capillary endothelial cells. FGFR-2 IIIc was localized in
the vascular endothelial cells and vascular smooth muscle cells in peri-
pancreatic tissues (C). Serial tissue sections indicate that CD31 is expressed
in the endothelial cells (D). Original magnification, 400.analyzed using a post hoc test. P  0.05 was considered
significant in all analyses. Computations were performed
using the StatView J version 5.0 software package (SAS
Institute, Cary, NC).
Results
FGFR Isoform Expression in Pancreatic Cancer
Cell Lines
To determine whether cultured human pancreatic cancer
cell lines express FGFR-2 IIIc, and to compare any such
expression with the expression of other FGFR isoforms,
q-PCR was performed using RNA from six human pan-
creatic cancer cell lines. FGFR-2 IIIc mRNA was ex-
pressed in all six cell lines. FGFR-2 IIIc mRNA levels were
highest in PANC-1 cells, intermediate in MIA PaCa-2
cells, and relatively low in KLM-1, Capan-1, PK-1, and
PK-8 cells (Figure 1A). The FGFR-2 IIIc level was 106-fold
higher in PANC-1 cells than in Capan-1 cells, which dem-
onstrates the extent of variability of FGFR-2 IIIc mRNA
levels across the different cell lines. PANC-1 and MIA
PaCa-2 cells (which express high levels of FGFR-2 IIIc)
expressed low FGFR-2 IIIb, whereas KLM-1, Capan-1,
PK-1, and PK-8 cells (which express low FGFR-2 IIIc) ex-
pressed higher FGFR-2 IIIb levels. A similar tendency was
observed in the expression levels of FGFR-1 and FGFR-3
isoforms in the pancreatic cancer cell lines (Figure 1A).
Next, immunoblotting with an anti-FGFR-2 IIIc antibody
was performed, using protein lysates from the same six
pancreatic cancer cell lines. FGFR-2 IIIc was expressed
Figure 3. Serial tissue sections of IHC and in
situ hybridization analyses of FGFR-2 IIIc in hu-
man pancreatic cancer tissues. A–C: FGFR-2 IIIc
and its mRNA were strongly expressed in pan-
creatic cancer cells (Ca) and fibroblast adjacent
to cancer cells (arrows). Sense probe did not
yield positive signals (C). D: Overall survival
curves showed a tendency to worse prognosis in
the FGFR-2 IIIc-positive group (solid line) (P 
0.1571). E: Duration to development of liver me-
tastasis after surgery was significantly shorter in
FGFR-2 IIIc-positive groups (solid line) than in
the FGFR-2 IIIc-negative groups (dotted line)
(P  0.0071). Original magnification, 200.
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IIIc protein was most abundant in PANC-1 cells and least
abundant in KLM-1, Capan-1, PK-1, and PK-8 cells (Fig-
ure 1B). Analysis by flow cytometry revealed similar ex-
pression patterns for FGFR-2 IIIc at the cell surface of the
PDAC cells as determined by Western blotting (Figure
1C). Overall, there was a close correlation between
FGFR-2 IIIc mRNA and protein levels in all six pancreatic
cancer cell lines.
FGFR-2 IIIc Expression in Pancreatic Cancer
Tissues
Immunohistochemical and in situ hybridization analysis of
PDAC samples was performed next, to determine
whether and in which cell type FGFR-2 IIIc is expressed
in human pancreatic cancer tissues. In the normal pan-
creas, weak FGFR-2 IIIc immunoreactivity was detected
in the endocrine islets, but not in ductal cells or capillary
endothelial cells (Figure 2A), and strong insulin immuno-
reactivity was present in the islets (Figure 2B). Moderate
FGFR-2 IIIc immunoreactivity was evident in the vascular
smooth muscle cells and endothelial cells of relatively
large vessels in the peripancreatic tissues (Figure 2C).
As expected, the vascular endothelial cells were positive
for CD31 (Figure 2D). By contrast to the epithelial cells in
the normal pancreas, there was strong FGFR-2 IIIc im-
munoreactivity in the cancer cells in 84 of 117 (71.8%)
PDAC samples (Figure 3A and Table 1). Moderate
FGFR-2 IIIc immunoreactivity was also evident in the fi-
broblasts adjacent to cancer cells (Figure 3A). Both the
cancer cells and the fibroblasts exhibited a moderately
strong FGFR-2 IIIc mRNA in in situ hybridization (Figure
3B). A sense probe used as negative control did not yield
a signal (Figure 3C).
FGFR-2 IIIc expression in the cancer cells did not
correlate with the clinicopathological factors (Table 1).
The overall 2-year survival rate for all 59 cases of PDAC
was 16.9%, and the overall survival rates of the FGFR-2
IIIc-positive group tended to be lower, but this difference
was not statistically significant (P  0.1571) (Figure 3D).
Time to development of liver metastasis after resection
was significantly shorter in the FGFR-2 IIIc-positive group
than in the FGFR-2 IIIc-negative group (P  0.0071)
(Figure 3E).
Figure 4. Consequences of FGFR-2 IIIc transfection in KLM-1 cells. A: KLM-1
cells were grown in RPMI 1640 medium with 10% FBS for 48 hours, total RNA
was extracted, and cDNA synthesis and q-PCR were performed. FGFR-2 IIIc
mRNA/18S ribosomal RNA levels were markedly increased in two FGFR-2
IIIc-transfected clones (clones 1 and 6), but not in mock-transfected cells
(mock-2 and mock-3). FGFR-2 IIIb mRNA expression was decreased in
FGFR-2 IIIc-transfected clones. B: Flow cytometry revealed greater numbers
of FGFR-2 IIIc-expressing cells on the cell surface in FGFR-2 IIIc-transfected
KLM-1 cells, compared with in mock-transfected cells Isotype-matched rabbit
IgG was used as a negative control (dotted line). C: FGFR-2 IIIc-transfected
KLM-1 cells and mock-transfected cells were morphologically indistinguish-
able, except for the presence of a greater number of cells undergoing mitosis
in the FGFR-2 IIIc-transfected KLM-1 cells (arrows). Original magnification
 200. D:When plated at a density of 5 103 cells per well in a 96-well plate
and grown for 72 hours in the RPMI 1640 medium supplemented with 10%
FBS, FGFR-2 IIIc-transfected KLM-1 cells demonstrated a significant increase
in proliferation, compared with mock cells. *P  0.05.
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To examine the role of FGFR-2 IIIc in pancreatic cancer
cells, we prepared FGFR-2 IIIc-overexpressing pancre-
atic cancer cells and mock-transfected cells as controls.
A full-length FGFR-2 IIIc cDNA was subcloned into
pIRES2-EGFP vector and stably transfected into KLM-1
cells, which express a low level of FGFR-2 IIIc. Capan-1
cells were not suitable for stable transfection, because,
although they expressed the lowest level of FGFR-2 IIIc,
these cells grow very slowly. FGFR-2 IIIc mRNA levels in
mock-transfected cells and FGFR-2 IIIc-transfected
KLM-1 cells were examined by q-PCR in relation to the
18S rRNA housekeeping gene. FGFR-2 IIIc/18S rRNA
levels were very high in FGFR-2 IIIc clones 1 and 6 and
low in the mock clones (Figure 4A). There was a parallel
but relatively small decrease in IIIb mRNA levels in the
FGFR-2 IIIc-transfected clones (Figure 4A). Moreover, as
analyzed with flow cytometry using the anti-FGFR-2 IIIc
antibody, high levels of FGFR-2 IIIc protein were evident
in FGFR-2 IIIc stably transfected KLM-1 cells (Figure 4B),
indicating that FGFR-2 IIIc was abundant on the cell
surface of these clones. FGFR-2 IIIc transfection did
not alter FGFR-3 IIIb or FGFR4 levels (see Supplemen-
tal Figure S1 at http://ajp.amjpathol.org), and the levels
of the other FGFRs were exceedingly low (data not
Figure 5. Effects of FGFR-2 IIIc on the proliferation and metastasis of KLM-1
subcutaneous tumors, compared with mock-transfected cells. B: The tumors
IIIc or anti-Ki-67 antibodies. FGFR-2 IIIc immunoreactivity was more str
mock-transfected cells (mock-3). The Ki-67 labeling index was higher in tumo
cell derived tumors. C: In the orthotopic model, FGFR-2 IIIc-transfected-K
Moreover, pancreatic tumor weights were significantly elevated in FGFR-2 I
metastases was also increased in FGFR-2 IIIc-transfected KLM-1 cells (arrow
*P  0.05; ***P  0.0001. Original magnification: 200 (B, top); 400 (B, bshown).Effects of FGFR-2 IIIc on Cell Morphology and
Proliferation
FGFR-2 IIIc-transfected KLM-1 cells and the correspond-
ing mock-transfected cells exhibited similar morpholo-
gies. However, the number of mitotic cells was greater in
the FGFR-2 IIIc-transfected KLM-1 cells than in mock-
transfected cells (Figure 4C). Moreover, FGFR-2 IIIc sta-
bly transfected KLM-1 cells demonstrated increased cell
proliferation, compared with mock cells (Figure 4D).
Effects of FGFR-2 IIIc on Subcutaneous Tumor
Formation in Nude Mice
To determine whether FGFR-2 IIIc modulated the in vivo
proliferation of pancreatic cancer cells, FGFR-2 IIIc-
transfected KLM-1 cells and mock-transfected cells were
injected subcutaneously in nude mice. Compared with
two different mock clones, FGFR-2 IIIc-transfected
KLM-1 clones 1 and 6 formed significantly larger tumors
(Figure 5A). There was strong FGFR-2 IIIc immunoreactivity
in the FGFR-2 IIIc-6-derived tumors and weak immunostain-
ing in the mock-3-derived tumors (Figure 5B). FGFR-2 IIIc
immunoreactivity was not detected in stromal cells in the
nude mice. Moreover, there was a marked increase in Ki-67
immunodeficient mice. A: FGFR-2 IIIc-transfected KLM-1 cells formed larger
oved, and immunohistochemical analysis was performed using anti-FGFR-2
xpressed in FGFR-2 IIIc-transfected cells (FGFR-2 IIIc-6), compared with
g from FGFR-2 IIIc-transfected KLM-1 cells, compared with mock-transfected
ells formed larger primary tumors, compared with mock-transfected cells.
fected cells, compared with mock-transfected cells. D: The number of liver
onjunction with an increase in liver weight in FGFR-2 IIIc-transfected cells.
; 600 (B, insets). Scale bar  10 mm.cells in
were rem
ongly e
rs arisin
LM-1 c
IIc-transimmunoreactivity in the FGFR-2 IIIc-6-derived tumors, com-
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Ki-67 labeling index in the subcutaneous tumor was twofold
higher in FGFR-2 IIIc-transfected KLM-1 cells, compared
with mock-transfected cells (Figure 5B).
Effects of FGFR-2 IIIc on Orthotopic Tumor
Formation and Liver Metastasis in NOG Mice
We next performed orthotopic implantation of FGFR-2
IIIc-transfected KLM-1 cells into NOG mice. FGFR-2 IIIc-
transfected KLM-1 cells formed larger intrapancreatic tu-
mors, compared with mock-transfected cells, and the
tumors were significantly heavier (Figure 5C). In addi-
tion, in this model, liver metastases were detected in all
four tumors derived from FGFR-2 IIIc-transfected cells,
but only in two of the four mock-transfected cell-de-
rived tumors. The number of liver metastases was also
increased in FGFR-2 IIIc-transfected cells, compared
with mock-transfected cells, and the livers of FGFR-2
IIIc-expressing tumors were significantly heavier (Fig-
ure 5D).
Orthotopic implantation was also performed in nude
mice, which have greater immunological responses than
NOG mice. In this model, the mean intrapancreatic tumorweight of the four FGFR-2 IIIc-6-derived tumors was
0.804  0.275 g. By contrast, the mean weight of the four
mock-3-derived tumors was 0.357  0.023 g. Moreover,
liver metastases were observed in only one mouse im-
planted with FGFR-2 IIIc-6 expressing tumor fragments,
and in none of the four mice implanted with mock-3
expressing tumor fragments.
Effects of FGFR-2 IIIc on Sphere Formation and
Side Population
To determine whether FGFR-2 IIIc contributed to CSC-
like features, we performed sphere formation and SP
Figure 6. Sphere formation and side population
assays in KLM-1 cells. KLM-1 cells were plated
on ultra-low attachment surface plates with se-
rum-free medium in the absence or presence of
FGF-2 (10 ng/mL) and EGF (20 ng/mL), and
cultured for 7 days. A: FGFR-2 IIIc-transfected
cells formed larger spheres, compared with
mock-transfected cells. Original magnification,
100. Scale bar  100 m. B: In serum-free
medium, FGFR-2 IIIc-transfected KLM-1 formed
more spheres, compared with mock and wild
cells. Addition of FGF-2 and EGF increased the
number of spheres, but FGFR-2 IIIc-transfected
KLM-1 cells still formed more spheres, compared
with mock or parental cells. C: After Hoechst
33342 dye staining, the side population of the
cells was measured by flow cytometry. D: The
proportion of SP cells was increased in FGFR-2
IIIc-transfected KLM-1 cells, compared with
mock and wild cells. E: FGF-2 (100 ng/mL) in-
creased ERK phosphorylation to a greater extent
in FGFR-2 IIIc-transfected KLM-1 cells, com-
pared with mock-transfected cells. Immunoblot-
ting for total ERK confirmed equivalent loading
of lanes. F: Apoptotic cell numbers were de-
creased in FGFR-2 IIIc-transfected cells, com-
pared with wild and mock-transfected cells. R1,
S phase; R2, G2M phase; R3, G0/G1 phase; R4,
sub-G0/G1. *P  0.05.
Table 2. Tumor Formation Ratio 5 Weeks after Subcutaneous
Injection of KLM-1 Cells in NOD/SCID Mice
Population
Tumor Formation Proportion by cells/mouse
[% (n/N)]
1.0  102 1.0  103 1.0  104 1.0  105
MP 0 (0/6) 0 (0/6) 33.3 (2/6) 66.7 (4/6)
SP 0 (0/6) 0 (0/6) 66.7 (4/6) 100 (6/6)MP, major population cells; SP, side population cells.
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cells. In the sphere formation assay, FGFR-2 IIIc-trans-
fected cells formed larger (Figure 6A) and more numer-
ous (Figure 6B) spheres, compared with mock-trans-
fected cells. Next, the proportion of SP fraction in
pancreatic cancer cells was determined by flow cytom-
etry (Figure 6C). FGFR-2 IIIc-transfected cells (FGFR-2
IIIc-1 and -6) also exhibited increased SP fractions, com-
pared with mock and wild (parental) cells (Figure 6D).
Subcutaneous injection of SP and MP cells of KLM-1 cells
into NOD/SCID mice, revealed that the tumors formed
when either 1.0  104 or 1.0  105 cells were injected,
but not when fewer cells were injected (Table 2). More-
over, the tumor formation ratio was always higher in SP
cells than in MP cells (Table 2).
Mitogenic signaling through FGFRs often involves ac-
tivation of the MAPK pathway. We therefore sought to
determine whether FGF-2-mediated activation of MAPK
was altered as a consequence of changes in the levels of
FGFR-2 IIIc. FGF-2 caused a rapid increase in p-ERK
levels in both mock-2 cells and FGFR-2 IIIc-6 transfected
PANC-1 cells. However, the phosphorylation levels of
ERK were markedly higher at 10 and 20 minutes after
FGF-2 addition in FGFR-2 IIIc-transfected KLM-1 cells
(Figure 6E). By contrast, the number of apoptotic cells
(sub G0/G1 phase) was decreased in FGFR-2 IIIc-trans-
fected cells (2.12% and 2.80%), compared with wild
(4.24%) and mock-transfected cells (3.57% and 4.25%)
(Figure 6F).
Transient Transfection of FGFR-2 IIIc in
Capan-1 Cells
To confirm our findings with KLM-1 cells, we next as-
sessed the consequences of transient transfection of
FGFR-2 IIIc in Capan-1 cells, because these cells exhib-
ited the lowest expression levels of FGFR-2 IIIc mRNA.
FGFR-2 IIIc mRNA (see Supplemental Figure S2A at
http://ajp.amjpathol.org) and protein levels (see Supple-
mental Figure S2B at http://ajp.amjpathol.org) were mark-
edly increased 72 hours after transfection. FGFR-2 IIIc-
transfected Capan-1 cells exhibited increased cell
proliferation, compared with wild and mock-transfected
cells (see Supplemental Figure S2C at http://ajp.
amjpathol.org). Moreover, FGF-2 and FGF-7 enhanced
the migration of Capan-1 cells, but this effect was statis-
tically greater in FGFR-2 IIIc-transfected cells, compared
with mock-transfected cells (see Supplemental Figure
S2D at http://ajp.amjpathol.org).
Figure 7. Effects of FGFR-2 IIIc down-regulation on PANC-1 cell prolif-
eration. FGFR-2 IIIc expression in PANC-1 cells was down-regulated using
siRNA against FGFR-2 IIIc transcripts. A: Two different siRNA sequences
against FGFR-2 IIIc mRNA (s275290 and s275291) down-regulated FGFR-2
IIIc expression at 24 hours after transfection. B: The percentage of FGFR-2
IIIc expressing cells was markedly decreased after transfection with
FGFR-2 IIIc siRNA, compared with negative siRNA-transfected cells. Iso-
type-matched rabbit IgG was used as negative control (dotted line). C:
The proliferation rates of these cells were lower than those in control
siRNA-transfected cells. D: After the addition of FGF-2, FGFR-2 IIIc siRNA-
transfected cells (s275290) showed decreased phosphorylation of ERK, compared
with negative siRNA-transfected cells. *P  0.05; **P  0.01.
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PANC-1 Cells
To further assess the importance of FGFR-2 IIIc in the
modulation of pancreatic cancer cell function, we next
sought to examine the consequences of down-regulating
FGFR-2 IIIc in PANC-1 cells, which expressed the highest
levels of FGFR-2 IIIc among all our cell lines. Accordingly,
two different sequences of siRNA against FGFR-2 IIIc
mRNA (s275290 and s275291) were used to induce the
down-regulation of FGFR-2 IIIc. Both siRNAs markedly
decreased FGFR-2 IIIc mRNA levels, compared with
those in control siRNA-transfected PANC-1 cells, at 24
hours after transfection (Figure 7A). By flow cytometry,
there were fewer FGFR-2 IIIc-expressing cells after trans-
fection with FGFR-2 IIIc siRNA (1.85% and 1.06%), com-
pared with cells transfected with negative siRNA (7.37%)
(Figure 7B). Basal proliferation rates of PANC-1 cells
transfected with either FGFR-2 IIIc siRNAs were signifi-
cantly lower than proliferation in control siRNA-trans-
fected cells (Figure 7C). Compared with negative siRNA-
transfected cells, FGFR-2 IIIc siRNA-transfected PANC-1
cells showed decreased ERK phosphorylation in re-
sponse to FGF-2 (Figure 7D).
Next, we sought to determine whether the anti-FGFR-2
IIIc antibody would inhibit the proliferation, migration, and
invasion of PANC-1 cells. Incubation of PANC-1 cells
with the anti-FGFR-2 IIIc antibody exerted a dose-de-
pendent inhibitory effect on the PANC-1 cell prolifera-
tion, maximal inhibition occurring at a concentration of
100 g/mL, whereas the control rabbit IgG was without
effect (Figure 8A). The anti-FGFR-2 IIIc antibody also
inhibited the migration of PANC-1 cells (Figure 8B), but
did not alter their invasion (Figure 8C). Time-lapse
analysis indicated that the anti-FGFR-2 IIIc antibody
markedly inhibited cell motility, compared with control
IgG (Figure 8D). Proliferation and migration of KLM-1
cells, which express very low levels of FGFR-2 IIIc,
were not inhibited by the addition of FGFR-2 IIIc anti-
Figure 8. Effects of an anti-human FGFR-2 IIIc antibody on PANC-1 cells. T
supplemented with 10% FBS and then incubated for 48 hours in the absen
different concentrations. A: Significant inhibition of proliferation was observe
with proliferation rates in the presence of the same concentrations of rabbit I
migration of PANC-1 cells (B), but did not alter their invasion (C). D: Inhibiti
antibody. In KLM-1 cells, which express very low levels of FGFR-2 IIIc, prolifera
***P  0.0001.bodies (Figure 8, A and D).Discussion
FGFR 2 IIIc and FGFR-2 IIIb/KGFR differ from each other
in the carboxyl-terminal half of the Ig-like region closest to
the intracellular domain, as a consequence of alternative
splicing.12 FGFR-2 IIIc is widely expressed in various
types of cancer cells, including adenocarcinomas, squa-
mous cell carcinomas, and transitional cell carcino-
mas.18–24 Most often, FGFR-2 expression correlates with
aggressive growth of the cancers and/or acquisition of
features consistent with epithelial-to-mesenchymal tran-
sition. In the present study, we determined that FGFR-2
IIIc mRNA was expressed in six pancreatic cancer cell
lines, and that the levels of the 100-kDa FGFR-2 IIIc
protein, as determined by immunoblotting with our highly
specific anti-FGFR-2 IIIc antibody, paralleled the corre-
sponding mRNA levels. To our knowledge, this is the first
report to document FGFR-2 IIIc expression at the protein
level in pancreatic cancer cells.
Using the same antibody, we documented that FGFR-2
IIIc was expressed in 73% of PDAC cases, which repre-
sents a higher frequency than the 41.5% frequency of
expression previously reported for FGFR-2 IIIb/KGFR.5
Although the presence of FGFR-2 IIIc correlated with
decreased duration to development of liver metastasis
after surgery, there was no significant correlation be-
tween FGFR-2 IIIc expression and prognosis. Previously,
we reported that FGFR-2 IIIb expression correlated with
an increased frequency of venous invasion but was not
associated with decreased survival. Thus, although the
presence of either of these two FGFR-2 isoforms in PDAC
is deleterious to the patient, other alterations dictate du-
ration of patient survival.5 Nonetheless, several distinct
lines of evidence suggest that FGFR-2 IIIc contributes to
the proliferation and migration of pancreatic cancer cells,
which may then secondarily promote retroperitoneal in-
vasion. First, FGFR-2 IIIc stably transfected KLM-1 cells
exhibited more rapid proliferation in vitro and in vivo than
mock-transfected cells. Second, transient transfection in
-1 cells (5  103 cells/100 L) were grown overnight in RPMI 1640 medium
n bars) or presence (shaded bars) of the anti-FGFR-2 IIIc antibody at four
centrations of 50 and 100 g/mL of the anti-FGFR-2 IIIc antibody, compared
hin 6 hours after its addition, the anti-FGFR-2 IIIc antibody also inhibited the
ll motility was also observed at 24 hours after addition of the anti-FGFR-2 IIIc
migration were not altered by the addition of FGFR-2 IIIc antibodies. *P 0.05;he PANC
ce (ope
d at con
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on of cePANC-1 cells with two different sequences of FGFR-2 IIIc
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highly specific anti-FGFR-2 IIIc antibody inhibited cell
proliferation in a dose-dependent manner. Nonethe-
less, it is also possible that increased FGFR-2 IIIc
expression in the stromal fibroblasts may contribute to
formation of chronic pancreatitis-like lesions in PDAC
through enhanced proliferation and migration of can-
cer-associated fibroblasts.
Two mechanisms may explain why increased expres-
sion of FGFR-2 IIIc induces pancreatic cancer cell pro-
liferation. First, multiple ligands bind with high affinity to
FGFR-2 IIIc, most notably FGFs 1, 2, 4, 6, 9, 17, and
18,13,14 and several of these ligands are overexpressed
in PDAC.15,33 Second, FGFR-2 IIIc receptor overexpres-
sion was associated with more pronounced MAPK phos-
phorylation, which is known to activate mitogenic signal-
ing. Although the changes in proliferation induced by
attenuating FGFR-2 IIIc expression in PANC-1 cells were
relatively modest, they were statistically significant. More-
over, it has been recently demonstrated that cancer cell
proliferation is only slightly increased in vivo, compared
with proliferation rates in normal cells, and that the cu-
mulative effects of this slight increase in proliferation lead
after many years to enhanced tumor size and, ultimately,
to gene alterations that lead to metastasis formation.34
Taken together, these observations suggest that patients
whose cancers express high levels of FGFR-2 IIIc may
have slightly more rapid disease progression.
In PDAC cell lines, FGFR-2 IIIc and IIIb levels tended to
be inversely related. Thus cell lines with high FGFR-2 IIIc
levels, such as PANC-1 and MIAPaCa-2 cells, had rela-
tively low levels of FGFR-2 IIIb and cell lines with high
FGFR-2 IIIb levels, such as PK-1 and PK-8 cells, had
relatively low levels of FGFR-2 IIIc. These observations
are consistent with recent studies showing that epithelial
splicing regulatory proteins 1 and 2 (ESRPs 1 and 2)
regulate the splicing of FGFR-2 IIIc and IIIb.35,36 ESRP-1
binds to the FGFR-2 auxiliary cis-element ISE/ISS-3, lo-
cated in the intron between exon IIIb and IIIc, and this
binding induces the expression of the FGFR-2 IIIb spe-
cific exon. Therefore, these splicing mechanisms may con-
tribute to the reciprocal switching between FGFR-2 IIIb and
IIIc isoforms. However, it is also possible that FGFR-2 IIIb
and IIIc isoforms are modulated at a transcriptional level
and/or through differential regulation of microRNAs that in
turn regulate their selective expression.
Although endogenous levels of FGFR-2 IIIb were low in
KLM-1 cells, engineered overexpression of FGFR-2 IIIc
(causing a 5- to 13-fold increase in FGFR-2 IIIc levels) in
these cells was associated with approximately a 40%
decrease in the already low endogenous FGFR-2 IIIb
levels. It is theoretically conceivable, therefore, that some
component of the biological consequences of FGFR-2
IIIc overexpression might also be due to an indirect con-
sequence of a slight lowering of endogenous FGFR-2 IIIb
levels.
Studies of CSCs in pancreatic cancer have relied on
sphere formation and SP assays and evaluation of CSC
markers such as CD24, CD44, CD133, epithelial specific
antigen (ESA), and CXCR4.37–40 However, CSC markers
in PDAC have not been accepted as definitive by allinvestigators. Furthermore, sphere formation in low-at-
tachment culture plates is induced by FGF-2, which is a
major ligand for FGFR-2 IIIc. We therefore used sphere
formation and SP assays; both measures were increased
in FGFR-2 IIIc-transfected cancer cells. It is not clear
whether this effect is due to an intrinsic action of in-
creased FGFR-2 IIIc levels or to activation of autocrine
FGF-2-dependent pathways, given that FGF-2 is a major
ligand for FGFR-2 IIIc. Irrespective of the mechanisms,
these observations suggest that FGFR-2 IIIc may con-
fer CSC-like characteristics to pancreatic cancer cells
and may contribute to the maintenance of a CSC niche
in PDAC.
Previously, FGFR-2 IIIc expression and epithelial-to-
mesenchymal transition transformation have been re-
ported to be closely related.25,26 Most reports indicate
that FGFR-2 IIIc induces epithelial-to-mesenchymal tran-
sition transformation, but in some reports FGFR-2 IIIc
correlates with mesenchymal-to-epithelial transition.22 In
the present study, FGFR-2 IIIc stably transfected KLM-1
cells did not exhibit a spindle-like appearance or higher
migration activity. However, further studies are necessary
to delineate the role of FGFR-2 IIIc in epithelial-to-mes-
enchymal transition in pancreatic cancer cells. Given that
FGFR-2 IIIc is not detected in normal cells in the pan-
creas, our findings raise the possibility that targeting
FGFR-2 IIIc has a potential to suppress pancreatic can-
cer cell proliferation without exerting deleterious effects
on normal cells. Thus, targeting FGFR-2 IIIc may allow for
the development of novel therapeutic strategies to im-
prove the survival of pancreatic cancer patients.
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